Navigation Links
Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
Date:2/7/2013

ssion ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:

Joshua Drumm , PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Z Trim Holdings, Inc. Records First Non-GMO Corn Sales
2. ARAMARK Introduces Worlds First Reusable Validated Sterile Goggle That Remains Clear When Irradiated
3. First-to-Market Online Identity Theft Protection - Allweb Technologies Launches AllWebID
4. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
5. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
6. Pathway BioLogic is Chosen by Easy Gardener to Formulate the U.S.’s First Microbial Enhanced Natural Water Soluble Plant Food
7. First bedside DNA test to be introduced in Czech Republic
8. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
9. Carolina Conceptions Announces the Delivery of their First Egg Freeze Pregnancy
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... 13 Accuri Cytometers, Inc. today announced the completion ... financing included current investors Fidelity Biosciences, Flagship Ventures, Baird ... InvestMichigan! Program co-managed by Credit Suisse. Accuri will ... provide additional working and growth capital to support the ...
... University a network of tiny sensors as small as ... determined intruder. Scattered outdoors on rocks, fence posts and ... dewdrops are a completely new and cost-effective system for safeguarding ... and his Tel Aviv University Faculty of Engineering team drew ...
... SAN DIEGO, July 10 David Koos, Chairman and CEO ... BMSN), today said that he believes that stem cell cord ... The Bio-Matrix CEO stated that hospitals throughout the world ... banks. "Hospitals from the U.S. to India are naturally ...
Cached Biology Technology:Accuri Cytometers Completes $4 Million Series D Financing 2Accuri Cytometers Completes $4 Million Series D Financing 3Accuri Cytometers Completes $4 Million Series D Financing 4Accuri Cytometers Completes $4 Million Series D Financing 5Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2Stem Cell Cord Blood 'Banking' Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc. 2
(Date:4/23/2014)... newly coined term for novels and films which focus on ... Copenhagen shows how these fictions serve as a mental laboratory ... change and imagine other living conditions. , "Global warming ... atmosphere; it is also a cultural phenomenon in which meaning ... films we see. And there are so many of them ...
(Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
(Date:4/22/2014)... to behave at the dinner tablecut up their food and ... Eating Behaviors , found that when 6-10 year old children ... such as drumsticks, whole apples, or corn on the cob ... cut. "They were twice as likely to disobey adults ... Professor and Director of the Cornell Food and Brand Lab. ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2
... have determined that most types of melanoma cells can ... form of skin cancer does not conform to the ... the researchers found that melanoma tumor cells can change ... making the malignant cells a stealthy, shape-shifting target for ...
... of California, San Diego NanoEngineers won a grant from ... tools to manufacture biodegradable frames around which heart tissues ... methods for growing tissues that mimic nature,s fine-grained details, ... grow replacement cardiac tissues for people who have suffered ...
... Elsevier, the leading publisher of scientific, technical and ... eBook collections available for advance purchase and to be ... The 2011 offerings total 439 titles spread across 24 ... between January 1 and December 31, 2011. ...
Cached Biology News:More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Nanoengineers aim to grow tissues with functional blood vessels 2Nanoengineers aim to grow tissues with functional blood vessels 3Elsevier announces the SciVerse ScienceDirect eBooks collection 2011 frontlist 2
... adapter allows the Thermo-Fast® ... AB-1000) PCR plates to ... ABI PRISM® 3700 capillary ... for information on the ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
... White lyophilized solid. PROTECT FROM LIGHT. PACKAGED ... of γ-secretase. Equipotently inhibits the release of ... 2.6 μM) and Aβ x-42 (ED ... cells stably transfected with the Amyloid Precursor ...
Biology Products: